NEW YORK – TScan Therapeutics said on Wednesday it would lay off 75 percent of its workforce and pause enrollment in an ongoing Phase III trial of its T-cell receptor (TCR)-engineered T-cell therapy ...

NEW YORK – AstraZeneca and Daiichi Sankyo said on Tuesday the European Commission approved its antibody-drug conjugate Enhertu (trastuzumab deruxtecan) in combination with Genentech's HER2 monoclonal ...

NEW YORK – Abbisko Therapeutics has begun treating cancer patients harboring KRAS alterations with the pan-KRAS Inhibitor ABSK211 in a Phase I trial. The company announced on Monday that the trial ...

BioNTech and Roche subsidiary Genentech are discontinuing testing of their jointly developed personalized cancer vaccine in colorectal cancer patients. The companies were testing the mRNA vaccine ...

Epic will use the funds to further develop its multi-analyte DefineMBC liquid biopsy and expand into other business areas. Epic Sciences, Biosplice Therapeutics Partner on Multiomic Profiling for ...

For patients with microsatellite instability of mismatch repair deficiency, the final decision cements access to the drug, which was previously offered provisionally.

The firm is testing the next dose level of RV-01 in a Phase I/IIa study after clearance from a safety and monitoring committee.

Three years after announcing the trial, the company dosed the first patient with the therapy, which targets kappa myeloma antigens.

This marks the company's first study in POLG-mediated primary mitochondrial disease, after completing a Phase I trial in healthy volunteers.

Regulators approved the FGFR1/2/3 inhibitor based on data showing a 42.5 percent objective response rate and 16.6 months of median overall survival.

CHICAGO – The American Society of Clinical Oncology will not recommend Grail's Galleri test for detecting cancers early after seeing data from a large, prospective randomized-controlled trial. Ahead ...